The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure
Open accessAbstract
BACKGROUND: An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, and a heart rate of 70 beats per minute or more. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of ivabradine, added to standard background therapy, in 19,102 patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more (including 12,049 patients with activity-limiting angina [class ≥II on the Canadian Cardiovascular Society scale, which ranges from I to IV, with higher classes indicating greater limitations on physical activity owing to angina]). We randomly assigned patients to placebo or ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute. The primary end point was a composite of death from cardiovascular causes or nonfatal myocardial infarction. RESULTS: At 3 months, the mean (±SD) heart rate of the patients was 60.7±9.0 beats per minute in the ivabradine group versus 70.6±10.1 beats per minute in the placebo group. After a median follow-up of 27.8 months, there was no significant difference between the ivabradine group and the placebo group in the incidence of the primary end point (6.8% and 6.4%, respectively; hazard ratio, 1.08; 95% confidence interval, 0.96 to 1.20; P=0.20), nor were there significant differences in the incidences of death from cardiovascular causes and nonfatal myocardial infarction. Ivabradine was associated with an increase in the incidence of the primary end point among patients with activity-limiting angina but not among those without activity-limiting angina (P=0.02 for interaction). The incidence of bradycardia was higher with ivabradine than with placebo (18.0% vs. 2.3%, P<0.001). CONCLUSIONS: Among patients who had stable coronary artery disease without clinical heart failure, the addition of ivabradine to standard background therapy to reduce the heart rate did not improve outcomes. (Funded by Servier; SIGNIFY Current Controlled Trials number, ISRCTN61576291.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the indication of stable coronary disease, none of these medications have been shown to reduce the risk of mortality or myocardial infarction.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [249]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationGibbons, R. J., Abrams, J., Chatterjee, K., Daley, J., DEEDWANIA, P. C., Douglas, J. S., Ferguson, T. B., Fihn, S. D., Fraker, T. D., Gardin, J. M., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02848-6 · Cited by 1,685
Guidelines on the management of stable angina pectoris: executive summary
Authors/Task Force Members, Fox, K. M., Garcia, M. A. A., Ardissino, D., Buszman, P. E., Camici, P. G., Crea, F., Daly, C., Backer, G. D., Hjemdahl, P., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl001 · Cited by 1,332
Self-citationHeart rate and cardiovascular mortality: The Framingham study
Kannel, W. B., Kannel, C., Paffenbarger, R. S., & Cupples, L. A. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90666-1 · Cited by 1,292
Böhm, M., Swedberg, K. B., Michel Komajda, N., BORER, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61259-7 · Cited by 1,100
Self-citationFox, K., Ford, I., Steg, P. G., Tendera, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61170-8 · Cited by 1,099
Self-citationResting Heart Rate in Cardiovascular Disease
Fox, K., Borer, J. S., Camm, A. J., Danchin, N., Ferrari, R., Lopez Sendon, J. L., Steg, P. G., Tardif, J.-C., Tavazzi, L., & Tendera, M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.079 · Cited by 1,062
Self-citationDiaz, A., Bourassa, M. G., Guertin, M.-C., & Tardif, J.-C. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi190 · Cited by 790
Self-citationFox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61171-x · Cited by 789
Self-citationTardif, J., Ford, I., Tendera, M., Bourassa, M. G., & Fox, K. M. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi586 · Cited by 580
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–485 of 485
Estudo prospectivo em angina refratária: evolução clínica e o papel da troponina ultrassensível
Poppi, N. T. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2015.tde-06112015-155028
Ivabradine: a SHIFT in heart failure management
Sasidharan, D. (2016) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2016.11.3.118
Die konservative Therapie der stabilen koronaren Herzerkrankung
Perné, A., & Münzel, T. F. (2014) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-014-3599-0
Heart Rate Modulation in Heart Failure
Chatterjee, N. A., & Lewis, G. D. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.043
Pharmaka mit Wirkung auf die glatte Muskulatur
Offermanns, S. (2016) · Springer-Lehrbuch · doi:10.1007/978-3-662-46689-6_40
Is Heart Rate a Norepiphenomenon in Heart Failure?
Hensey, M., & O’Neill, J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0764-3
Medical treatment in multivessels coronary disease
Fattirolli, F., Pratesi, A., & Venturini, S. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000442
Investigation of the mechanisms mediating genetic associations with atrial fibrillation
Martin, R. I. R. (2015)
Hidalgo, F. J., & Anguita, M. P. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.12.025
Role of Ivabradine in the Treatment of Heart Failure: Comments on the ESC 2016 Guidelines
Hidalgo, F. J., & Anguita, M. P. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.12.045
Metabolic interventions in heart failure
Booij, H. G. (2017) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Riccio, C., Gulizia, M. M., Colivicchi, F., Lenarda, A. D., Musumeci, G., Faggiano, P. M., Abrignani, M. G., Rossini, R., Fattirolli, F., Valente, S., et al. (2017) · PubMed · doi:10.1093/eurheartj/sux021 · Cited by 2
Medical Management of Stable Angina: Systematic Therapeutic Approach
Mahmood, M., & Hoque, H. (2017) · University Heart Journal · doi:10.3329/uhj.v12i1.34014
THERAPY OF STABLE ANGINA OF EFFORT BY TRIPLE COMBINATIONS OF ANTIANGINAL DRUGS IN GERIATRIC PRACTICE
Канорский, С. Г., & Smolenskaya, N. V. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-12-62-67
New Therapeutic Strategies in Heart Failure
Rossano, J. W., Jefferies, J. L., & Dreyer, W. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802393-8.00044-2
Editorial commentary: Treatment of refractory angina: An ongoing challenge
Thadani, U. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.12.005
Thampi, S., Sheth, S., Madu, C., Chionchio, A., & Loukas, E. (2018) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000672
Lofrano‐Alves, M. S. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-11012018-090809
Ivabradine for systolic heart failure
Meade, C. M., & Clements, J. N. (2018) · JAAPA · doi:10.1097/01.jaa.0000530305.69021.02
Kim, J. (2018) · Hip & Pelvis · doi:10.5371/hp.2018.30.1.1
DRUG THERAPY FOR DIMINISHED MYOCARDIAL CONTRACTILITY
Mazur, N. A., & Miklishanskaya, S. V. (2018) · Vrach · doi:10.29296/25877305-2018-06-03
Traitement de l'insuffisance cardiaque
Capelle, A., Armoiry, X., & Aulagner, G. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-75077-9.00010-4
Barylski, M., Lelonek, M., Mamcarz, A., & Mastalerz–Migas, A. (2019) · Folia Cardiologica · doi:10.5603/fc.2018.0120
Efficacy of ivabradine for heart failure
Xue, E.-Z., Zhang, M., & Liu, C. (2019) · Medicine · doi:10.1097/md.0000000000015075
Wall Shear Stress and Atherosclerotic Plaque Progression
Xing, R. (2019) · RePub (Erasmus University Rotterdam)
Recently Approved Pharmacologic Agents to Improve Outcomes in Heart Failure
Booth, D. C., & Rajagopalan, N. (2019) · Contemporary cardiology · doi:10.1007/978-3-030-19131-3_8
Chronic heart failure: actual aspects of treatment in real clinical practice
Трухан, Д. И., & Davydov, E. L. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-16-50-58
Moser, G. (2019) · Cardiologia Hungarica · doi:10.26430/chungarica.2019.49.4.290
Mohebali, D., & Sabe, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-47868-1_9
Ivabradine for the Therapy of Chronic Stable Angina Pectoris
Kim, S. (2020) · Korean Circulation Journal · doi:10.4070/kcj.2020.0266
Lanfear, D. E., Neaton, K. R., Lu, C., Liu, Y., & Dent-Acosta, R. E. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00196-1
Dolzhenko, M. N. (2016) · Medicine of Ukraine · doi:10.37987/1997-9894.2016.9(205).207227
ROLE OF HEART RATE REDUCTION WITH IVABRADINE IN LEFT VENTRICULAR FAILURE
Batool, S., Waris, J., Sajid, M. U., Nisar, S., Khan, I. M., & Mushtaq, H. (2020) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v70i6.4869
Zhang, F., Jiang, W., Liu, Y., Li, L., Wang, R., & Li, Y. (2021) · Archives of Medical Science · doi:10.5114/aoms/113625
A present view on ivabradine in the therapy of cardiovascular diseases
Slíva, J. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.063
Tratamiento farmacológico del síndrome coronario crónico
Rivas, S. G., Flórez, J. M. V., Ruiz, J. M. M., & Gómez, J. L. Z. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.06.021
Drug-Induced Atrial Fibrillation / Atrial Flutter
Ostroumova, O. D., Сергеевна, Ч. М., Кочетков, А. И., Vorobieva, A. E., Bakhteeva, D. I., Korchagina, S. P., Bondarets, O. V., Boyko, N. D., & Sychev, D. A. (2022) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2021-12-11
Koronare Herzkrankheit: Aktuelle Aspekte der Behandlung
Neumann, F. (2019) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2019.10.04.01
Eschenhagen, T. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_27
Stable Ischemic Heart Disease and Approach to Chronic Chest Pain
Hanna, E. B. (2022) · Wiley eBooks · doi:10.1002/9781119832737.ch3
Antiarrhythmic agents and torsades de pointes
Wass, S. Y., & Chung, M. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821446-6.00005-5
Eschenhagen, T. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_28
(2015) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2015.3.0312
Diagnosis and management of stable angina
(2021) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2021.1.115357
Eschenhagen, T. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_26
Eschenhagen, T. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_28
Eschenhagen, T. (2015) · Springer eBooks · doi:10.1007/978-3-662-47186-9_25
Eschenhagen, T. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_29
Cowie, M. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780198766223.003.0054
Ahn, M., Yoo, B., Lee, S. J., Kim, J., Son, J., Park, Y. J., Cho, D., Kim, S. H., Kang, D. R., Lee, H., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4126910
Eschenhagen, T., & Weil, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_7
Naji, F. H., Berro, M., Šuran, D., & Kanič, V. (2021) · Acta Medico-Biotechnica · doi:10.18690/actabiomed.212
Overview of Ivabradine Drug: Use and History
Lubis, M. (2023) · Buletin Farmatera · doi:10.30596/bf.v8i1.12751
Managing Stable Coronary Artery Disease in Diabetes
Koulouridis, I., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_23
CARDIOLOGIA EM FOCO: PREVENÇÃO, DIAGNÓSTICO E TRATAMENTOS ATUAIS
Almeida, A. B., & Horevicht, C. M. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809
dos Santos, A. P. F., Viviani, H., Marim, J. R., & Peixoto, M. M. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809p159
Т.Л., М. (2023) · Український медичний часопис · doi:10.32471/umj.1680-3051.156.246246
Unusual Manifestation of Atrioventricular Dissociation in A 63 Year-Old Man and Clinical Insights
Chan, Y.-H. W. (2023) · Journal of the Hong Kong College of Cardiology · doi:10.55503/2790-6744.1515
Heart rate reduction with ivabradine in heart failure
Böhm, M., & Michel Komajda, N. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780198891628.003.0045
Postoperatif junctional ektopik taşikardi ve ivabradine genel bakış
Sarı, Y. E. (2023) · Ümraniye Pediatri Dergisi - Journal of Umraniye Pediatrics · doi:10.14744/upd.2023.64935
Eschenhagen, T., & Weil, J. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_7
Palatini, P. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-39315-0_5
The underappreciated value of resting heart rate in post-myocardial infarction follow-up
Girerd, N. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132059
Ivabradine: sinus rhythm control in heart failure
Barillà, F., Carbonaro, M., kindy, S. A., & Mangieri, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822972-9.00041-9
Advancing heart failure management: A comparative analysis of Ivabradine and Sacubitril / valsartan
Choudhary, S., Jadhav, S., & Gaikwad, S. (2024) · International Journal of Pharmaceutical and Clinical Research · doi:10.33545/26647591.2024.v6.i1b.83
Rizk, S. I. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2024.tde-22052024-140427
Kubica, J., Adamski, P., Buszman, P. P., Fabiszak, T., Foryś, J., Gajda, R., Gąsior, M., Gierlotka, M. J., Gil, R. J., Hajdukiewicz, T., et al. (2024) · Medical Research Journal · doi:10.5603/mrj.103601
Gu, T., Zhang, Y., Hu, S., Zhang, J., Wu, X., Liu, X., Shao, X., Wang, L., Zhao, J., Liu, T., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(25)01431-7
(2025) · International Journal of Integrative Cardiology · doi:10.47275/2690-862x-150
Cheng, K., & de Silva, R. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.05.005
Pharmacological role of ivabradine in cardiovascular disease: A Review
Nabi, B., Singh, I., & Gill, N. S. (2025) · International Journal of Pharmacology and Clinical Research · doi:10.33545/26647613.2025.v7.i2a.95
New therapeutic strategies for heart failure
Rossano, J. W., Dreyer, W. J., & Jefferies, J. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13279-7.00056-0
Tratamiento de la angina estable
Álvarez, B. Á., Martínez, J. M., Bermejo, R. M. A., Álvarez, D. I., Veloso, P. R., García‐Acuña, J. M., & González‐Juanatey, J. R. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.10.003
Eschenhagen, T., & Weil, J. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_7
Д.С., К. (2026) · Український медичний часопис · doi:10.32471/umj.1680-3051.274187
Ibrahimov, F., Huseynova, K., Babayeva, N., Shahuseynov, S., & Jamilov, R. (2026) · Journal of Heart Disease and Therapy · doi:10.71295/jhdt.2026.03.1.06
Cardioprotection contre les lésions d’ischémie-reperfusion par réduction de la fréquence cardiaque
Betancourt, S. D. (2015) · theses.fr (ABES) · doi:10.70675/8d5deb30zd61dz437czbce5zb5f0416eecb0
Lee, J. M., Kim, Y., Lee, S. Y., Kwon, W., Hwang, D., Chon, M. K., Joh, H. S., Lee, S. H., Lee, K. Y., Seo, Y. H., et al. (2026) · Journal of Cardiovascular Intervention · doi:10.54912/jci.2026.0018
Hamzah, K. A., Kurmasha, Y. H., Rasheed, W. M., Al‐Shammari, A. S., Shahzaib, M., Akoum, A., Shweliya, M. A., Ramadan, A., Taii, H. A., & Refaat, M. M. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001840
Brie, D. M., Mornoş, C., Tîrziu, A., Popescu, R., & Brie, A. D. (2026) · Pharmaceuticals · doi:10.3390/ph19091370
Ivabradine Use and Exercise Capacity Post-Atrial Switch Repair for Transposition of Great Arteries
WILSON, W. M., burchill, L., Finch, S., Grigg, L., Irving, L., Harrington, H. A., Zentner, D., & Cheung, M. M. H. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103276
Imamura, T. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07975-3
Ivabradin ohne Effekt bei der stabilen Angina
Aumiller, J. (2014) · CardioVasc · doi:10.1007/s15027-014-0424-8
Ivabradin kann Progression der KHK nicht aufhalten
Einecke, D. (2014) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-014-3443-6
Metadata
- Authors
- Fox, K., Ford, I., Steg, P. G., Tardif, J.-C., Tendera, M., & Ferrari, R.
- Affiliations
- Inserm (FR)
- University of Glasgow (GB)
- Montreal Heart Institute (CA)
- University of Ferrara (IT)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-18
- Volume
- 371
- Issue
- 12
- Pages
- 1091-1099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2153622558
- Cited by
- 486
- References
- 19
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 30 · 2023: 34 · 2022: 29 · 2021: 29 · 2020: 27 · 2019: 44 · 2018: 35 · 2017: 49 · 2016: 95 · 2015: 68 · 2014: 18
- FWCI
- 52.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10149)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Keywords
- ivabradine, stable coronary artery disease, heart rate reduction, cardiovascular mortality, myocardial infarction, bradycardia, non-inferiority, left ventricular dysfunction, target heart rate, drug safety and efficacy, atrial fibrillation
- MeSH terms
- Ivabradine, Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Benzazepines, Cardiovascular Diseases, Coronary Artery Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heart Failure, Heart Rate, Humans, Male, Middle Aged, Risk, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Intention to Treat Analysis, Angina, Stable
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
